Non-Small Cell Lung Cancer and RAS-mutated thoracic malignancies
Revolution Medicines Inc. concentrates on non-small cell lung cancer, with studies addressing RAS-mutated NSCLC, including tumors driven by KRAS G12C and KRAS G12D alterations. Its research activity includes patients with previously treated disease and advanced presentations requiring new targeted treatment options.
- RAS G12C-mutated NSCLC
- RAS G12D-mutant NSCLC
- Previously treated lung cancer
Clinical interest in this area spans targeted approaches for mutation-defined lung cancer and combination treatment strategies involving established anti-cancer agents.
Pancreatic Ductal Adenocarcinoma
The sponsor funds research in pancreatic ductal adenocarcinoma, including metastatic PDAC and resected PDAC after prior treatment. This reflects a focus on both advanced and surgically managed pancreatic cancer populations.
- Metastatic pancreatic ductal adenocarcinoma
- Resected pancreatic ductal adenocarcinoma
- Post-chemotherapy pancreatic cancer
Its trials in this field examine therapeutic strategies for pancreatic cancer across the disease course, including settings where standard options remain limited.
KRAS-mutated Solid Tumors
Revolution Medicines Inc. also studies advanced solid tumors carrying KRASG12C and KRASG12D mutations. These programs extend beyond a single cancer type and include mutation-selected populations with shared oncogenic drivers.
- Advanced KRASG12C-mutated solid tumors
- Advanced KRASG12D-mutated solid tumors
- RAS-mutated advanced solid tumors
This area includes research across multiple solid tumor histologies where KRAS alterations are central to disease biology.
Colorectal Cancer and broader advanced solid tumor research
The sponsor’s portfolio includes colorectal cancer within a wider set of advanced solid tumors. These studies support evaluation of mutation-directed therapies in gastrointestinal and other solid tumor cancers with advanced disease characteristics.
- Colorectal cancer
- Advanced solid tumor
- Mutation-defined solid cancers
Research in this domain reflects interest in tumor types where RAS pathway alterations may shape treatment selection.
Combination oncology therapy
Across its studies, Revolution Medicines Inc. evaluates combination regimens in oncology, including use with pembrolizumab and other anti-cancer agents. These programs are centered on advanced mutation-driven cancers requiring multi-agent treatment approaches.
- Combination anti-cancer therapy
- Immunotherapy combinations
- Advanced mutation-driven cancer treatment
The research scope includes both monotherapy and combination strategies in solid tumors with RAS-associated biology.
